Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl(Medical University of Graz), Ryan B. Corcoran(Massachusetts General Hospital), Christine M. Parseghian(The University of Texas MD Anderson Cancer Center), Haley Ellis(Broad Institute), Ferran Fece de la Cruz(Harvard University), Bryanna L. Norden(Massachusetts General Hospital), Leontios Pappas(Harvard University), Haley Barnes(Massachusetts General Hospital), Bennett Adam Caughey(Harvard University), A.R. Parikh(Harvard University), Preeti Patel(Indo Soviet Friendship College of Pharmacy), Rebecca S. Heist(Massachusetts General Hospital), Sara Ehnstrom(Harvard University), Samuel J. Klempner(Broad Institute), Justin F. Gainor(Harvard University), W. Marston Linehan(Harvard University), Aaron N. Hata(Harvard University), Alvin A. Morales-Giron(Harvard University), Jonathan Kim(Cornell University), Hiroyuki Matsubara(Harvard University), H. Nakamura(Harvard University), Erich James Kushner(Harvard University), A Vakaris(Harvard University), Scott Kopetz(The University of Texas MD Anderson Cancer Center)
Cited by 49
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k